AI in medical imaging: How Riverain Technologies is shaping the future of radiology

Riverain Technologies is making significant advancements in medical imaging by expanding its global reach and enhancing its AI-powered diagnostic tools. In 2024, the company entered eight new countries and added nearly 50 new customers, strengthening its presence in radiology. At the same time, it introduced new FDA-cleared technology for coronary artery calcium (CAC) scoring in ungated scans without contrast. This advancement allows for opportunistic screening of coronary heart disease, the leading cause of death in the U.S. and worldwide.

The company’s ClearRead™ solutions are designed to help radiologists detect cardiothoracic diseases with greater speed and accuracy. By integrating Artificial Intelligence in Health Tech, Riverain aims to reduce false positives, improve diagnostic confidence, and optimize patient outcomes. With continued growth and technological innovation, Riverain Technologies is playing a key role in the evolution of radiology.

AI-powered diagnostic accuracy

Advancements in Artificial Intelligence in Health Tech are transforming the way radiologists detect and diagnose cardiothoracic diseases. Riverain Technologies is at the forefront of this shift, integrating AI into its ClearRead solutions to enhance imaging accuracy, reduce interpretation time, and improve patient outcomes. By leveraging AI-driven tools, the company is helping radiologists make faster, more confident diagnoses, ultimately reshaping the future of medical imaging.

ClearRead CT: Improving detection with AI

Riverain’s ClearRead CT software is a cornerstone of its AI-powered imaging suite. Designed to assist radiologists in detecting lung nodules and assessing coronary artery calcium levels, this tool significantly improves diagnostic efficiency.

A study conducted at the University of Washington School of Medicine found that ClearRead CT Vessel Suppression reduced radiologists’ reading times by 36%, enabling faster identification of pulmonary nodules. These findings were presented at the 2024 Radiological Society of North America (RSNA) annual meeting, underscoring the software’s clinical value.

With its ability to enhance image clarity, ClearRead CT minimizes distractions caused by surrounding structures, allowing radiologists to focus on critical areas. The newly FDA-cleared CAC scoring function further expands its capabilities, enabling early detection of heart disease without requiring contrast-enhanced scans. This development is particularly valuable for opportunistic screening in patients who may not have undergone traditional cardiac assessments.

ClearRead Xray: Advancing chest imaging

In addition to CT imaging, Riverain’s ClearRead Xray solution is transforming chest X-ray interpretation. By utilizing Clear Visual Intelligence™, the software provides an unobstructed view of the chest, improving the detection of lung abnormalities. Features such as volumetric analysis for nodule detection, portable line and tube enhancement, and pneumothorax alerts streamline radiologists’ workflows and enhance patient care.

With the rise of Artificial Intelligence in Health Tech, solutions like ClearRead Xray are becoming essential for hospitals and healthcare institutions looking to optimize diagnostic accuracy. By reducing interpretation time and improving confidence in findings, Riverain’s technology supports radiologists in making timely, life-saving decisions.

Global expansion and key partnerships

In 2024, Riverain Technologies expanded into eight new countries, including New Zealand, Australia, Saudi Arabia, Spain, the United Kingdom, South Africa, Italy, and Belgium. This global reach has allowed more radiologists to integrate ClearRead solutions into their workflows, improving diagnostic accuracy worldwide.

In North America, Riverain partnered with RevealDX, a Canadian company specializing in malignancy prediction scores. This collaboration enhances radiologists’ ability to assess lung cancer risk and recommend appropriate follow-up care. The company also strengthened its presence in the U.S. Department of Veterans Affairs (VA) medical centers, increasing its total number of partner sites to 104, with 52 new locations added in 2024.

Innovation and industry impact

Participation in leading medical conferences: Riverain Technologies has actively participated in major industry events, presenting its advancements and sharing insights on Artificial Intelligence in Health Tech.

The company participated in the 2024 RSNA annual meeting, the European Congress of Radiology, the Society of Thoracic Radiology annual meeting, and conferences hosted by the American Cancer Society and the American Association for Bronchology and Interventional Pulmonology (AABIP). These events provided a platform for Riverain to demonstrate the impact of its technology and engage with medical professionals worldwide.

Growth in channel partnerships: Riverain’s strategic collaborations have contributed to a 240% year-over-year increase in channel partner activity. By working with healthcare institutions, technology providers, and research organizations, the company has expanded its influence in the medical imaging sector. These partnerships have been instrumental in accelerating the adoption of AI-powered diagnostic tools across various healthcare settings.

Virtual training for a growing customer base: As demand for ClearRead solutions grows, Riverain has launched a virtual applications training platform to support its expanding global customer base. This initiative ensures that radiologists and healthcare professionals can effectively integrate AI-powered tools into their workflows, maximizing the benefits of advanced imaging technology. The training platform provides in-depth guidance on software features, best practices for interpretation, and case-based learning modules.

Shaping the future of AI in radiology

With its commitment to innovation, Riverain Technologies continues to redefine diagnostic imaging through AI-powered solutions. By expanding its global footprint, strengthening industry collaborations, and enhancing its ClearRead technology, the company is setting new standards for efficiency and accuracy in radiology.

As Artificial Intelligence in Health Tech becomes an integral part of medical imaging, Riverain is positioned to lead the transformation of cardiothoracic diagnostics. By providing radiologists with the tools needed for faster, more precise interpretations, Riverain is not only improving patient care but also shaping the future of AI-driven healthcare solutions.